China NMPA Product Recall - Femoral stem assembly

Zimmer Biomet (Shanghai) Medical International Trading Co., Ltd. has initiated a voluntary Class II recall for specific femoral stem components. This action, announced by the National Medical Products Administration (NMPA) on January 6, 2020, arose after a supplier responsible for final cleaning of certain Zimmer Biomet products received a warning letter from the U.S. FDA. Zimmer Biomet's subsequent evaluation focused on products processed by this supplier prior to March 2018. The investigation indicated that the supplier's earlier cleaning process might have resulted in elevated bacterial endotoxin levels and residual debris on the product surfaces. While clinical data from over 200,000 marketed products globally, including 57 related complaints, suggested expected performance and confirmed product sterility was not compromised, the supplier's quality standards at that time were inconsistent with Zimmer Biomet's current, stricter requirements. Out of an abundance of caution, and acknowledging the potential for local tissue reactions despite no increased risk of infection, Zimmer Biomet opted to recall affected batches. This proactive measure ensures adherence to high-quality standards under NMPA oversight, with products manufactured after the March 2018 cleaning upgrade remaining unaffected.